$17.15 1.13 (6.18%)
19:00 EDT CRY Stock Quote Delayed 30 Minutes
Previous Close -
Market Cap 628.24M
PE Ratio -245.00
Volume (Avg. Vol.) 255,100
Day's Range 17.04 - 17.98
52-Week Range 12.63 - 31.77
Dividend & Yield N/A (N/A)
CRY Stock Predictions, Articles, and Cryolife News
- From InvestorPlace
- From the Web
Small caps can be fertile ground for investors. These 17 small-cap stocks are high-risk stocks in some cases -- but have paths to doubling.
11 Health Care Equipment & Supplies stocks are moving up in their overall rating this week, according to the Portfolio Grader database. Every one of these is graded an "A" ("strong buy") or "B" overall ("buy").
These are the 10 best healthcare stocks to buy going forward after the 2016 presidential election shook up the whole sector.
Think small when thinking about big profits in this market. These seven stocks may look small, but they pack a wallop.
A company's own top management tend to have the best inside view into the business, so when company officers make major buys, investors are wise to take notice. Presumably the only reason an insider would take their hard-earned cash and use it to buy stock of their company in the open market, is that they expect to make money — maybe they find the stock very undervalued, or maybe they see exciting progress within the company, or maybe both..
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100..
Bargain hunters are wise to pay careful attention to insider buying, because although there are many various reasons for an insider to sell a stock, presumably the only reason they would use their hard-earned dollars to make a purchase, is that they expect to make money. Today we look at two noteworthy recent insider buys.
From Seeking Alpha
CryoLife (NYSE:CRY) acquires Florida-based Ascyrus Medical for up to $200M, including $60M cash and $20M shares of CryoLife's common stock in upfront payment.Ascyrus is a privately-held developer of the Ascyrus Medical Dissection Stent (AMDS), the world's first aortic arch remodeling device used for the treatment of acute Type A aortic dissections. The acquisition will result in CryoLife's high single-digit revenue growth beginning in 2021 and non-GAAP earnings growth over the next five years."We believe the addition of the AMDS to our product offerings will make a meaningful contribution to our future growth as it gives us immediate access to the combined $100+ million EU and Canadian markets and has the potential to expand our worldwide addressable market by approximately $540 million," says CEO Pat Mackin.Stock up 1.33% AH.Previously: CryoLife EPS beats by $0.07, beats on revenue(July 30)
Navellier RatingsPowered by Portfolio Grader